IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy

Glioblastoma multiforme (GBM), which accounts for approximately 54% of all gliomas, is one the most fatal diseases with a limited survival time. Only one-third of GBM patients survive for one year and less than 5% of GBM patients live more than five years [1]. Concurrent and adjuvant temozolomide (TMZ)-based chemoradiotherapy, followed by six months of TMZ maintenance therapy is the current standard strategy for the treatment of GBM patients up to 70 years of age [2,3]. However, it has been recently reported that GBM patients who have undergone concurrent and adjuvant TMZ-based chemoradiotherapy have a high likelihood of developing pseudoprogression disease (psPD) [4,5].

Source: Clinical Neurology and Neurosurgery - October 12, 2016 Category: Neurosurgery Authors: Hailong Li, Jiye Li, Gang Cheng, Jianning Zhang, Xuezhen Li Source Type: research